32 Stocks Moving In Monday’s Mid-Day Session
Gainers
Nuvectis Pharma, Inc. (NASDAQ: NVCT) jumped 191.2% to $9.47. The company, on Friday, priced its IPO at $5 per share.
Mid-Day Market Update: US Stocks Down; Nasdaq Falls 50 Points
Midway through trading Monday, the Dow traded down 0.10% to 35,053.40 while the NASDAQ fell 0.36% to 14,046.74. The S&P also fell, dropping, 0.26% to 4,488.93.
Also check out this: Executives Sell Over $45M Of 5 Stocks
Cerence Q1 EPS $0.59 Beats $0.51 Estimate, Sales $94.43M Beat $94.38M Estimate
Cerence (NASDAQ:CRNC) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.51 by 15.69 percent. This is unchanged from the same period last year. The company reported quarterly
A Look Into Cerence’s Debt
Shares of Cerence (NASDAQ:CRNC) decreased by 39.65% in the past three months. Before we understand the importance of debt, let us look at how much debt Cerence has.
RBC Capital Downgrades Cerence to Sector Perform, Lowers Price Target to $77
RBC Capital analyst Joseph Spak downgrades Cerence (NASDAQ:CRNC) from Outperform to Sector Perform and lowers the price target from $95 to $77.
Where Cerence Stands With Analysts
Over the past 3 months, 7 analysts have published their opinion on Cerence (NASDAQ:CRNC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Goldman Sachs Maintains Buy on Cerence, Lowers Price Target to $103
Goldman Sachs maintains Cerence (NASDAQ:CRNC) with a Buy and lowers the price target from $115 to $103.